Company intelligence / Profile preview

CARO

Farmington, Connecticut, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

CaroGen is a clinical-stage biotechnology company focused on developing transformative vaccines and immunotherapies using its proprietary AAV-based platform. The company's lead program, CARG-201, is an immunotherapy designed to treat chronic hepatitis B by stimulating a comprehensive immune response against the virus. CaroGen is also leveraging its platform to develop treatments for various cancers, including colorectal and liver cancer, as well as other infectious diseases. By utilizing a unique viral vector technology, the company aims to provide durable and effective therapeutic solutions for patients with high unmet medical needs.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineGene therapyAAV-based therapyImmunotherapy
Industry: Biotech

Partnerships

Yale UniversityUniversity of Connecticut

Beyond the preview

Go deeper on CARO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CARO.

Explore the full profile